Skip to main content

Table 1 Patient characteristics

From: Safety and efficacy of exercise training in adults with Pompe disease: evalution of endurance, muscle strength and core stability before and after a 12 week training program

 

Group 1 (n = 12)

Group 2 (n = 11)

Total group (n = 23)

P-value*

Male gender (%)

7 (58 %)

5 (45 %)

12 (52 %)

0.54

Age in years (range)

45.4 (19.6-70.5)

46.6 (32.9-66.1)

46.0 (19.6-70.5)

0.85

Disease duration in years (range)

15.5 (8.1-28.1)

16.1 (6.0-32.1)

15.8 (6.0-32.1)

0.83

ERT duration in years (range)

3.3 (1.4-6.5)

3.0 (1.3-3.6)

3.1 (1.3-6.5)

0.96

Training sessions (max. 36)

33 (27–36)

32 (24–35)

32 (24–36)

0.70

  1. Group 1 trained in weeks 1–12 and Group 2 trained in weeks 13–24
  2. ERT enzyme replacement therapy
  3. *For the difference between group 1 and 2 (chi-2 test for proportions and Wilcoxon signed rank test for continuous data)
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172